Chi Van Dang

Cancer Research’s Editor-in-Chief

Chi Van Dang is the newly appointed Editor-in-Chief of Cancer Research and is currently the scientific director of the Ludwig Institute for Cancer Research, where he oversees the execution of Ludwig’s scientific strategy to advance the prevention, diagnosis, and treatment of cancer. He is also a professor at the Wistar Institute's Molecular and Cellular Oncogenesis Program. His work focuses on cancer cell metabolism, and his laboratory established the first mechanistic link between the MYC cancer gene and cellular energy metabolism.

An AACR member since 1996, Dang previously served on the editorial board of Cancer Research and Cancer Discovery, two of the AACR's most prestigious journals. He has held numerous committee posts at the AACR. He chaired the AACR's Clinical and Translational Cancer Research Grants Committee, served on the Science Education Committee and AACR Team Science Award Selection Committee, and served with distinction as a co-chair of the 2017 AACR Annual Meeting Program Committee.

Prior to joining the Ludwig Institute for Cancer Research and the Wistar Institute in 2017, Dr. Dang served as the director of the Abramson Cancer Center at the University of Pennsylvania and as the John H. Glick Professor of Medicine, a position he has held since 2011. Before moving to Philadelphia, Dr. Dang was the Johns Hopkins Family Professor in Oncology Research and vice dean for research at Johns Hopkins University School of Medicine. He directed the Hopkins Institute for Cell Engineering and was a professor of medicine, pathology, oncology, and cell biology, with joint appointments in molecular biology and genetics. Dang has a bachelor's degree in chemistry from the University of Michigan, a PhD in chemistry from Georgetown University, and a medical degree from Johns Hopkins University. He completed a fellowship at the University of California, San Francisco.

Dang was recently appointed to the National Cancer Institute (NCI) Blue Ribbon Panel that has informed the scientific direction and goals of Vice President Joe Biden’s National Cancer Moonshot Initiative. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and the Association of American Physicians, and is chair of the NCI’s Board of Scientific Advisors.

A selection of Dr. Dang’s recent research articles from the AACR family of journals is provided below:

• A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics.
  Claret L, Jin JY, Ferté C, Winter H, Girish S, et al. Clinical Cancer Research July 2018.
• Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
  Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, et al. Clinical Cancer Research November 2017.
• Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
  Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, et al. Clinical Cancer Research October 2017.
• A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
  Paik PK, Shen R, Berger MF, Ferry D, Soria JC, et al. Clin Cancer Research September 2017.
• AACR Project GENIE: Powering Precision Medicine through an International Consortium.
  AACR Project GENIE Consortium. Cancer Discovery August 2017.
• Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
  Pailler E, Oulhen M, Borget I, Remon J, Ross K, et al. Cancer Research May 2017.
• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
  Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, et al. Cancer Discovery June 2017.
• JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.
  Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC. Cancer Discovery February 2017.